CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

SMid Biotech Analyst Joseph holds a conference call with CEO Evans on November 12 at 2 pm hosted by JPMorgan.Webcast Link Published first on ...

Leerink Partners has recently raised Beam Therapeutics Inc (BEAM) stock to Outperform rating, as announced on November 6, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...

Fintel reports that on November 6, 2024, Leerink Partners upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today. Patrick Trucchio has ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had ...

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM.